ES2150948T3 - Analogos de pth. - Google Patents

Analogos de pth.

Info

Publication number
ES2150948T3
ES2150948T3 ES93915814T ES93915814T ES2150948T3 ES 2150948 T3 ES2150948 T3 ES 2150948T3 ES 93915814 T ES93915814 T ES 93915814T ES 93915814 T ES93915814 T ES 93915814T ES 2150948 T3 ES2150948 T3 ES 2150948T3
Authority
ES
Spain
Prior art keywords
pth
alpha
amino acid
amino
joined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93915814T
Other languages
English (en)
Inventor
Wilfried Bauer
Robin Breckenridge
Francois Cardinaux
Frank Gombert
Hermann Gram
Paul Ramage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215009A external-priority patent/GB9215009D0/en
Priority claimed from GB929226415A external-priority patent/GB9226415D0/en
Priority claimed from GB929226859A external-priority patent/GB9226859D0/en
Priority claimed from GB929226861A external-priority patent/GB9226861D0/en
Priority claimed from GB939301692A external-priority patent/GB9301692D0/en
Priority claimed from GB939301691A external-priority patent/GB9301691D0/en
Priority claimed from GB939307673A external-priority patent/GB9307673D0/en
Priority claimed from GB939308033A external-priority patent/GB9308033D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of ES2150948T3 publication Critical patent/ES2150948T3/es
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPUESTOS DE PTH QUE TIENEN ACTIVIDAD COMO PTH Y COMPRENDEN AL MENOS UNA MODIFICACION, ESTANDO DICHA MODIFICACION EN O 1) AL MENOS UN RADICAL SELECCIONADO DE UN L- O D-(ALFA)-AMINOACIDO, C26 ALCOXICARBONILO Y C1-8 ALKILO OPCIONALMENTE SUSTITUIDO, C28 ALQUENILO, C2-8 ALKINILO, ARALKILO, ARALQUENILO O C36CICLOALKILO-C1-4ALKILO Y UNIDOS AL GRUPO AMINO TERMINAL DEL COMPUESTO PTH, Y/O AL MENOS UN RADICAL SELECCIONADO DE C26 ALCOXICARBONILO Y C1-8 ALKILO OPCIONALMENTE SUSTITUIDO, C28 ALQUENILO, C2-8 ALKINILO, ARALKILO, ARALQUENILO O C36CICLOALKILO-1-4ALKILO Y UNIDO A UNO O MAS GRUPOS AMINO DE CADENAS LATERALES DEL COMPUESTO PTH; O 2) AL MENOS UNA UNIDAD DE (ALFA)-AMINOACIDO EN LAS POSICIONES 1 A 38 DE UNA SECUENCIA PTH QUE OCURRE NATURALMENTE SIENDO REEMPLAZADA POR UNA UNIDAD DE AMINOACIDO NATURAL O NO NATURAL OPCIONALMENTE EN FORMA PROTEGIDA, EN DONDE LAS UNIDADES DE (ALFA)-AMINOACIDOS SE PRESENTAN EN POSICIONES 1 Y 2 EN EL LIMITE DEL AMINO DE LA SECUENCIA PTH PUEDE SER REEMPLAZADO POR UN PSEUDOPEPTIDO, O UNA COMBINACION DE TALES MODIFICACIONES, EN FORMA LIBRE O EN FORMA DE SAL, TIENEN ACTIVIDAD FARMACOLOGICA, POR EJEMPLO PARA PREVENIR O TRATAR TODAS LAS CONDICIONES OSEAS ASOCIADAS CON UNA DISMINUCION EN AUMENTO O RESORCION DE CALCIO O EN LA QUE FIJACION DEL CALCIO EN EL HUESO ES DESEABLE.
ES93915814T 1992-07-15 1993-07-06 Analogos de pth. Expired - Lifetime ES2150948T3 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB929215009A GB9215009D0 (en) 1992-07-15 1992-07-15 Organic compounds
GB929226415A GB9226415D0 (en) 1992-12-18 1992-12-18 Organic compounds
GB929226861A GB9226861D0 (en) 1992-12-23 1992-12-23 Organic compounds
GB929226859A GB9226859D0 (en) 1992-12-23 1992-12-23 Organic compounds
GB939301692A GB9301692D0 (en) 1993-01-28 1993-01-28 Organic compounds
GB939301691A GB9301691D0 (en) 1993-01-28 1993-01-28 Organic compounds
GB939307673A GB9307673D0 (en) 1993-04-14 1993-04-14 Organic compounds
GB939308033A GB9308033D0 (en) 1993-04-19 1993-04-19 Organic compounds
PCT/EP1993/001749 WO1994002510A2 (en) 1992-07-15 1993-07-06 Analogs of pth

Publications (1)

Publication Number Publication Date
ES2150948T3 true ES2150948T3 (es) 2000-12-16

Family

ID=27571302

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93915814T Expired - Lifetime ES2150948T3 (es) 1992-07-15 1993-07-06 Analogos de pth.

Country Status (25)

Country Link
US (2) US20050009147A1 (es)
EP (1) EP0672057B1 (es)
JP (1) JP3164463B2 (es)
KR (1) KR100321651B1 (es)
CN (1) CN1051769C (es)
AT (1) AT408100B (es)
AU (1) AU672790B2 (es)
CA (1) CA2100423C (es)
CH (1) CH688195A5 (es)
CZ (1) CZ286889B6 (es)
DE (2) DE4393381B4 (es)
DK (1) DK0672057T3 (es)
ES (1) ES2150948T3 (es)
FI (1) FI113872B (es)
GB (1) GB2269176B (es)
GR (1) GR3035089T3 (es)
HK (1) HK1004896A1 (es)
HU (2) HUT70459A (es)
IL (1) IL106326A (es)
NO (1) NO319448B1 (es)
NZ (1) NZ248137A (es)
PT (1) PT672057E (es)
SG (1) SG63625A1 (es)
SK (1) SK283485B6 (es)
WO (1) WO1994002510A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
TW273513B (es) * 1993-10-27 1996-04-01 Chugai Pharmaceutical Co Ltd
CA2126299C (en) * 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
US6110892A (en) * 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
CA2178894A1 (en) * 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use
US6544949B1 (en) * 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
EP1352912A1 (en) * 1996-08-02 2003-10-15 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JP4122061B2 (ja) * 1996-08-02 2008-07-23 ナショナル リサーチ カウンシル オブ カナダ 骨粗鬆症の治寮のための副甲状腺ホルモン類似体
AP9901686A0 (en) 1997-05-14 1999-12-31 Rhone Poulenc Rorer Pharma Peptide parathyroid hormone analogs.
EP1721617A3 (en) * 1997-07-22 2008-05-28 Chugai Seiyaku Kabushiki Kaisha Dental therapeutics containing parathyroid hormone
CN1210059C (zh) 1997-09-09 2005-07-13 弗·哈夫曼-拉罗切有限公司 使用PTHrP类似物的骨折愈合
US7531621B1 (en) 1998-05-05 2009-05-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. PTH2 receptor selective compounds
EP1123401A1 (en) 1998-10-22 2001-08-16 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
AU1633200A (en) 1998-11-25 2000-06-13 General Hospital Corporation, The Human parathyroid hormone modifications, preparation and use
US7169567B1 (en) 1998-12-31 2007-01-30 The General Hospital Corporation Screening assay utilizing the PTH receptor
US7057012B1 (en) 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
WO2000039278A2 (en) * 1998-12-31 2000-07-06 The General Hospital Corporation Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
WO2001023521A2 (en) 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
AU2003207512B2 (en) 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
CA2496618A1 (en) 2002-05-23 2003-12-04 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
AU2002951372A0 (en) * 2002-09-13 2002-09-26 St Vincent's Institute Of Medical Research Parathyroid hormone-like polypeptides
AU2003220380A1 (en) 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
JP4871128B2 (ja) 2003-07-17 2012-02-08 ザ ジェネラル ホスピタル コーポレイション 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
SG159551A1 (en) 2005-02-11 2010-03-30 Amylin Pharmaceuticals Inc Gip analog and hybrid polypeptides with selectable properties
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
WO2007028632A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2008019062A2 (en) * 2006-08-04 2008-02-14 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2672907C (en) 2006-10-13 2013-08-06 Eli Lilly And Company Pegylated pth as pth receptor modulators and uses thereof
MX346714B (es) 2007-08-01 2017-03-24 The General Hospital Corp * Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
US8642536B2 (en) 2008-10-17 2014-02-04 Wisconsin Alumni Research Foundation Method of making biologically active alpha-beta peptides
US8563513B2 (en) 2009-03-27 2013-10-22 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
CN103002906B (zh) 2010-05-13 2017-12-29 总医院有限公司 甲状旁腺激素类似物及其应用
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
CA2829020A1 (en) * 2011-03-01 2012-09-07 Sloan-Kettering Institute For Cancer Research Parathyroid hormone analogs, compositions and uses thereof
US20170037086A1 (en) * 2014-04-09 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
MX2021007179A (es) 2018-12-20 2021-09-28 Ksq Therapeutics Inc Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1).
IL302352A (en) 2020-10-30 2023-06-01 Ksq Therapeutics Inc Solid state forms of substituted pyrazolopyrimidines and uses thereof
WO2023066881A1 (en) 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US5420242A (en) * 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
US5001223A (en) * 1987-05-26 1991-03-19 Merck & Co., Inc. Parathyroid hormone antagonists with enhanced metabolic properties
EP0293158A3 (en) * 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroid hormone antagonists
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
DE3725320A1 (de) * 1987-07-30 1989-02-09 Biotechnolog Forschung Gmbh Expressionsvektoren und verfahren unter deren verwendung zur gewinnung von cro/ss-galaktosidase/pth-fusionsproteinen und von pth
US4968669A (en) * 1988-05-09 1990-11-06 Merck & Co., Inc. Parathyroid hormone antagonists
EP0411096A1 (de) * 1989-02-23 1991-02-06 Gesellschaft für Biotechnologische Forschung mbH (GBF) Pth-varianten kodierende dna-sequenzen, pth-varianten, expressionsvektor, bakterieller wirt, verwendung und therapeutische zusammensetzung
CA2040264A1 (en) * 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
US5093233A (en) * 1990-04-25 1992-03-03 Merck & Co., Inc. Antagonists with position 13 modification
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
JPH0532696A (ja) * 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
AU9103791A (en) * 1990-12-21 1992-07-22 Allelix Biopharmaceuticals Inc. Oxidation resistant variants of parathyroid hormone
ATE138102T1 (de) * 1991-02-19 1996-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von cysteinfreien peptiden
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis

Also Published As

Publication number Publication date
DE4393381T1 (de) 1995-04-27
DK0672057T3 (da) 2000-12-27
ATA903993A (de) 2001-01-15
EP0672057A1 (en) 1995-09-20
FI950171A7 (fi) 1995-03-13
HU211856A9 (en) 1995-12-28
NO319448B1 (no) 2005-08-15
CN1099801A (zh) 1995-03-08
CN1051769C (zh) 2000-04-26
NO950123D0 (no) 1995-01-12
GB2269176B (en) 1997-01-08
GR3035089T3 (en) 2001-03-30
KR940005670A (ko) 1994-03-22
CZ8895A3 (en) 1995-10-18
DE4393381B4 (de) 2008-07-17
WO1994002510A3 (en) 1994-05-26
IL106326A (en) 1997-09-30
CH688195A5 (de) 1997-06-13
WO1994002510A2 (en) 1994-02-03
IL106326A0 (en) 1994-04-12
NO950123L (no) 1995-03-15
GB2269176A (en) 1994-02-02
HU9500115D0 (en) 1995-03-28
CZ286889B6 (en) 2000-07-12
CA2100423C (en) 2005-06-14
US20050009147A1 (en) 2005-01-13
JPH06184198A (ja) 1994-07-05
FI113872B (fi) 2004-06-30
JP3164463B2 (ja) 2001-05-08
PT672057E (pt) 2001-02-28
AT408100B (de) 2001-08-27
SK283485B6 (sk) 2003-08-05
HK1004896A1 (en) 1998-12-11
EP0672057B1 (en) 2000-09-20
SG63625A1 (en) 1999-03-30
AU4156693A (en) 1994-01-20
AU672790B2 (en) 1996-10-17
SK4395A3 (en) 1995-06-07
FI950171A0 (fi) 1995-01-13
NZ248137A (en) 1995-12-21
GB9314384D0 (en) 1993-08-25
KR100321651B1 (ko) 2002-05-13
HUT70459A (en) 1995-10-30
US20080318838A1 (en) 2008-12-25
CA2100423A1 (en) 1994-01-16

Similar Documents

Publication Publication Date Title
ES2150948T3 (es) Analogos de pth.
ATE266043T1 (de) Peptidanaloge des menschlichen basischen myelinproteins
ES8602847A1 (es) Procedimiento para preparar un analogo polipeptido inhibidor de renina
DK1137666T3 (da) GLP-1-analoger
TW200833365A (en) Neuronal exocytosis inhibiting peptides
ES545760A0 (es) Procedimiento para preparar peptidos liberadores de la hormona del crecimiento.
ES8500218A1 (es) Un procedimiento para preparar peptidos sinteticos del tipo de las calcitoninas.
ES8700232A1 (es) Un procedimiento para producir 1a,25-dihidroxi-26,27-dime- tilcolecalciferol
MX171351B (es) Desinfectante liquido concentrado
ES2012720A6 (es) Procedimiento para la obtencion de sales de adicion de acido de taurina o glicina amidada.
ATE77628T1 (de) Peptidverbindungen.
FI864246A0 (fi) N-substituerade 3-piperidin- eller 3-pyridinkarboxylsyror samt deras derivat.
ES2063383T3 (es) Vacunas contra la coccidiosis.
ES2137945T3 (es) Analogos de gnrh.
DK482185D0 (da) Peptider, deres fremstilling og anvendelse som laegemidler
ATE31314T1 (de) Cyclische peptide mit somatostatin-wirkung.
MX9304251A (es) Compuestos variantes de la hormona paratiroidea, proceso para su produccion y composiciones farmaceuticas que los contienen.
ATE86260T1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
ES2060650T3 (es) Peptidos de rinovirus humanos.
ES2058290T3 (es) Analogos de somatostatina terapeuticos.
KR890700673A (ko) 돼지 성장호르몬 아날로그
ES8504680A1 (es) Un procedimiento para la preparacion de derivados de benzamida
MX9400781A (es) Uso de polifosfatos acidos de sodio para el tratamiento de carne y aves.
AR245696A1 (es) Derivados del acido (7-(hetero)ariloxi-naftalin-2-il-oxi)-alcancarboxilico
ES2067040T3 (es) Procedimiento para la preparacion de acidos metilenbisfosfonicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 672057

Country of ref document: ES